1
|
Kraemer R, Baty F, Smith HJ, Minder S, Gallati S, Brutsche MH, Matthys H. Assessment of functional diversities in patients with Asthma, COPD, Asthma-COPD overlap, and Cystic Fibrosis (CF). PLoS One 2024; 19:e0292270. [PMID: 38377145 PMCID: PMC10878531 DOI: 10.1371/journal.pone.0292270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Accepted: 09/17/2023] [Indexed: 02/22/2024] Open
Abstract
The objectives of the present study were to evaluate the discriminating power of spirometric and plethysmographic lung function parameters to differenciate the diagnosis of asthma, ACO, COPD, and to define functional characteristics for more precise classification of obstructive lung diseases. From the databases of 4 centers, a total of 756 lung function tests (194 healthy subjects, 175 with asthma, 71 with ACO, 78 with COPD and 238 with CF) were collected, and gradients among combinations of target parameters from spirometry (forced expiratory volume one second: FEV1; FEV1/forced vital capacity: FEV1/FVC; forced expiratory flow between 25-75% FVC: FEF25-75), and plethysmography (effective, resistive airway resistance: sReff; aerodynamic work of breathing at rest: sWOB), separately for in- and expiration (sReffIN, sReffEX, sWOBin, sWOBex) as well as static lung volumes (total lung capacity: TLC; functional residual capacity: FRCpleth; residual volume: RV), the control of breathing (mouth occlusion pressure: P0.1; mean inspiratory flow: VT/TI; the inspiratory to total time ratio: TI/Ttot) and the inspiratory impedance (Zinpleth = P0.1/VT/TI) were explored. Linear discriminant analyses (LDA) were applied to identify discriminant functions and classification rules using recursive partitioning decision trees. LDA showed a high classification accuracy (sensitivity and specificity > 90%) for healthy subjects, COPD and CF. The accuracy dropped for asthma (~70%) and even more for ACO (~60%). The decision tree revealed that P0.1, sRtot, and VT/TI differentiate most between healthy and asthma (68.9%), COPD (82.1%), and CF (60.6%). Moreover, using sWOBex and Zinpleth ACO can be discriminated from asthma and COPD (60%). Thus, the functional complexity of obstructive lung diseases can be understood, if specific spirometric and plethysmographic parameters are used. Moreover, the newly described parameters of airway dynamics and the central control of breathing including Zinpleth may well serve as promising functional marker in the field of precision medicine.
Collapse
Affiliation(s)
- Richard Kraemer
- Centre of Pulmonary Medicine, Hirslanden Hospital Group, Salem-Hospital, Bern, Switzerland
- Department of Paediatrics, University of Bern, Bern, Switzerland
- School of Biomedical and Precision Engineering (SBPE), University of Bern, Bern, Switzerland
| | - Florent Baty
- Department of Pneumology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Hans-Jürgen Smith
- Medical Development, Research in Respiratory Diagnostics, Berlin, Germany
| | - Stefan Minder
- Centre of Pulmonary Medicine, Hirslanden Hospital Group, Salem-Hospital, Bern, Switzerland
| | - Sabina Gallati
- Department of Paediatrics, University of Bern, Bern, Switzerland
- Hirslanden Precise, Genomic Medicine, Hirslanden Hospital Group, Zollikon/Zürich, Switzerland
| | - Martin H. Brutsche
- Department of Pneumology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Heinrich Matthys
- Department of Pneumology, University Hospital of Freiburg, Freiburg, Germany
| |
Collapse
|
2
|
Spoor DS, van den Bogaard VAB, Sijtsema NM, Van der Meer P, de Bock GH, Langendijk JA, Maduro JH, Crijns APG. A comparison of cardiovascular and pulmonary morbidities and risk factors in breast cancer survivors compared to an age-matched female control group in the Lifelines prospective population cohort. Breast 2023; 70:49-55. [PMID: 37331094 DOI: 10.1016/j.breast.2023.06.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 04/21/2023] [Accepted: 06/05/2023] [Indexed: 06/20/2023] Open
Abstract
PURPOSE To provide more insight into late treatment-related toxicities among breast cancer (BC) survivors by comparing morbidities and risk factors between BC survivors and age-matched controls. MATERIALS AND METHODS All female participants diagnosed with BC before inclusion in Lifelines, a population-based cohort in the Netherlands, were selected and matched 1:4 to female controls without any oncological history on birth year. Baseline was defined as the age at BC diagnosis. Outcomes were obtained from questionnaires and functional analyses performed at entry to Lifelines (follow-up 1; FU1) and several years later (FU2). Cardiovascular and pulmonary events were defined as morbidities that were absent at baseline but present at FU1 or FU2. RESULTS The study consisted of 1,325 BC survivors and 5,300 controls. The median period from baseline (i.e., BC treatment) to FU1 and FU2 was 7 and 10 years, respectively. Among BC survivors more events of heart failure (OR: 1.72 [1.10-2.68]) and less events of hypertension (OR: 0.79 [0.66-0.94]) were observed. At FU2, more electrocardiographic abnormalities were found among BC survivors compared to controls (4.1% vs. 2.7%, respectively; p = 0.027) and Framingham scores for the 10-year risk of coronary heart disease were lower (difference: 0.37%; 95% CI [-0.70 to -0.03%]). At FU2, BC survivors had more frequently a forced vital capacity below the lower limit of normal than controls (5.4% vs. 2.9%, respectively; p = 0.040). CONCLUSION BC survivors are at risk of late treatment-related toxicities despite a more favourable cardiovascular risk profile compared to age-matched female controls.
Collapse
Affiliation(s)
- D S Spoor
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - V A B van den Bogaard
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - N M Sijtsema
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - P Van der Meer
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - G H de Bock
- Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - J A Langendijk
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - J H Maduro
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - A P G Crijns
- Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
| |
Collapse
|
3
|
Verbanck S, Van Parijs H, Schuermans D, Vinh-Hung V, Storme G, Fontaine C, De Ridder M, Verellen D, Vanderhelst E, Hanon S. Lung Restriction in Breast Cancer Patients after Hypofractionated Tomotherapy and Conventional 3D Conformal Radiotherapy: a 10-year Follow-up. Int J Radiat Oncol Biol Phys 2022; 113:561-569. [DOI: 10.1016/j.ijrobp.2022.02.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 02/09/2022] [Accepted: 02/13/2022] [Indexed: 10/19/2022]
|
4
|
Van Parijs H, Vinh-Hung V, Fontaine C, Storme G, Verschraegen C, Nguyen DM, Adriaenssens N, Nguyen NP, Gorobets O, De Ridder M. Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer. BMC Cancer 2021; 21:1177. [PMID: 34736429 PMCID: PMC8569957 DOI: 10.1186/s12885-021-08916-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Accepted: 10/26/2021] [Indexed: 11/17/2022] Open
Abstract
Background Long-term prospective patient-reported outcomes (PRO) after breast cancer adjuvant radiotherapy is scarce. TomoBreast compared conventional radiotherapy (CR) with tomotherapy (TT), on the hypothesis that TT might reduce lung-heart toxicity. Methods Among 123 women consenting to participate, 64 were randomized to CR, 59 to TT. CR delivered 50 Gy in 25 fractions/5 weeks to breast/chest wall and regional nodes if node-positive, with a sequential boost (16 Gy/8 fractions/1.6 weeks) after lumpectomy. TT delivered 42 Gy/15 fractions/3 weeks to breast/chest wall and regional nodes if node-positive, 51 Gy simultaneous-integrated-boost in patients with lumpectomy. PRO were assessed using the European Organization for Research and Treatment of Cancer questionnaire QLQ-C30. PRO scores were converted into a symptom-free scale, 100 indicating a fully symptom-free score, 0 indicating total loss of freedom from symptom. Changes of PRO over time were analyzed using the linear mixed-effect model. Survival analysis computed time to > 10% PRO-deterioration. A post-hoc cardiorespiratory outcome was defined as deterioration in any of dyspnea, fatigue, physical functioning, or pain. Results At 10.4 years median follow-up, patients returned on average 9 questionnaires/patient, providing a total of 1139 PRO records. Item completeness was 96.6%. Missingness did not differ between the randomization arms. The PRO at baseline were below the nominal 100% symptom-free score, notably the mean fatigue-free score was 64.8% vs. 69.6%, pain-free was 75.4% vs. 75.3%, and dyspnea-free was 84.8% vs. 88.5%, in the TT vs. CR arm, respectively, although the differences were not significant. By mixed-effect modeling on early ≤2 years assessment, all three scores deteriorated, significantly for fatigue, P ≤ 0.01, without effect of randomization arm. By modeling on late assessment beyond 2 years, TT versus CR was not significantly associated with changes of fatigue-free or pain-free scores but was associated with a significant 8.9% improvement of freedom from dyspnea, P = 0.035. By survival analysis of the time to PRO deterioration, TT improved 10-year survival free of cardiorespiratory deterioration from 66.9% with CR to 84.5% with TT, P = 0.029. Conclusion Modern radiation therapy can significantly improve long-term PRO. Trial registration Trial registration number ClinicalTrials.govNCT00459628, April 12, 2007 prospectively. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08916-z.
Collapse
Affiliation(s)
- Hilde Van Parijs
- Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101 Laarbeeklaan, 1090, Brussels, Belgium
| | - Vincent Vinh-Hung
- Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101 Laarbeeklaan, 1090, Brussels, Belgium. .,Centre Hospitalier Universitaire (CHU) de Martinique, Fort-de-France, France.
| | - Christel Fontaine
- Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101 Laarbeeklaan, 1090, Brussels, Belgium
| | - Guy Storme
- Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101 Laarbeeklaan, 1090, Brussels, Belgium
| | | | - Dung M Nguyen
- School of Medicine, Vietnam National University, Ho Chi Minh City, Vietnam
| | - Nele Adriaenssens
- Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101 Laarbeeklaan, 1090, Brussels, Belgium
| | | | - Olena Gorobets
- Centre Hospitalier Universitaire (CHU) de Martinique, Fort-de-France, France.,Ukrainian Military Medical Academy, Kiev, Ukraine
| | - Mark De Ridder
- Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101 Laarbeeklaan, 1090, Brussels, Belgium
| |
Collapse
|
5
|
Evolution of lung function and chest CT 6 months after COVID-19 pneumonia: Real-life data from a Belgian University Hospital. Respir Med 2021; 182:106421. [PMID: 33901788 PMCID: PMC8053365 DOI: 10.1016/j.rmed.2021.106421] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 03/22/2021] [Accepted: 04/15/2021] [Indexed: 12/22/2022]
Abstract
Introduction Most post COVID-19 follow-up studies are limited to a follow-up of 3 months. Whether a favorable evolution in lung function and/or radiological abnormalities is to be expected beyond 3 months is uncertain. Materials and methods We conducted a real-life follow-up study assessing the evolution in lung function, chest CT and ventilation distribution between 10 weeks and 6 months after diagnosis of COVID-19 pneumonia. Results Seventy-nine patients were assessed at 6 months of whom 63 had chest CT at both follow-up visits and 46 had multiple breath washout testing to obtain lung clearance index (LCI). The study group was divided into a restrictive (n = 39) and a non-restrictive subgroup (n = 40) based on TLC z-score. Restriction was associated with a history of intubation, neuromuscular blockade use and critical illness polyneuropathy. Restriction significantly improved over time, but was not resolved by 6 months (median TLC z-score of −2.2 [IQR: −2.7; −1.5] at 6 months versus −2.7 [IQR: −3.1; −2.1] at 10 weeks). LCI did not evolve between both follow-up visits. Symptoms and chest CT score improved irrespective of restriction. Conclusion We observed a disconnect between the improvement of COVID-19 related symptoms, chest CT lesions, and corresponding lung function. While CT imaging is almost normalized at 6 months, a further reduction of pulmonary restriction may be hoped for beyond 6 months in those patients showing restriction at their first follow-up visit.
Collapse
|
6
|
Valverde-Ampai W, Palma-Rozas G, Conei D, Marzuca-Nassr GN, Medina-González P, Escobar-Cabello M, Del Sol M, Muñoz-Cofré R. Efectos del tratamiento con quimioterapia y radioterapia concomitante sobre los volúmenes pulmonares en mujeres con cáncer de mama en Talca, Chile. REVISTA DE LA FACULTAD DE MEDICINA 2020. [DOI: 10.15446/revfacmed.v68n2.73402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Introducción. El cáncer de mama (CM) es la enfermedad crónica no transmisible más frecuente y letal en mujeres. La información disponible sobre el impacto de sus diversos tratamientos en el sistema respiratorio es controversial.Objetivo. Determinar el efecto del tratamiento con quimioterapia y radioterapia concomitante en los volúmenes pulmonares de un grupo de mujeres con CM en Talca, Chile.Materiales y métodos. Estudio de casos y controles. La muestra (n=22) se dividió en dos grupos: control (n=11) y con CM (n=11). Para medir la capacidad vital forzada, los volúmenes pulmonares y la resistencia de las vías aéreas, se usó la prueba de pletismografía corporal. Para determinar la normalidad de los datos, se usó la prueba Shapiro-Wilks y, según sus resultados, se utilizó la prueba de t-Student o la de U de Mann-Whitney; se consideró un nivel de significancia de p<0.05.Resultados. Los flujos ventilatorios no presentaron diferencias significativas entre los dos grupos, mientras que los volúmenes pulmonares en el grupo con CM experimentaron una disminución significativa en las variables capacidad inspiratoria (CI) y volumen residual (VR) (p<0.05).Conclusión. Las mujeres con CM y que fueron tratadas con quimioterapia y radioterapia concomitante experimentaron una disminución en su CI y su VR en comparación con el grupo control, lo que podría impactar su calidad de vida.
Collapse
|
7
|
O'Donnell DE, Webb KA, Langer D, Elbehairy AF, Neder JA, Dudgeon DJ. Respiratory Factors Contributing to Exercise Intolerance in Breast Cancer Survivors: A Case-Control Study. J Pain Symptom Manage 2016; 52:54-63. [PMID: 26975626 DOI: 10.1016/j.jpainsymman.2016.01.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2015] [Revised: 01/07/2016] [Accepted: 02/13/2016] [Indexed: 11/20/2022]
Abstract
CONTEXT Breast cancer survivors often experience activity-related dyspnea and exercise intolerance, but the underlying mechanisms remain unknown. OBJECTIVES We evaluated physiological contributors to reduced peak oxygen uptake (VO2), with particular attention to the role of respiratory impairment. METHODS We compared symptom assessments, respiratory and peripheral muscle strength, pulmonary function, and ventilatory responses to symptom-limited incremental treadmill exercise in 29 women who had survived breast cancer and 29 age-matched healthy controls. RESULTS Peak VO2 was reduced more than 20%, on average, in the cancer group compared with controls (P < 0.001). Slopes of dyspnea intensity ratings over ventilation or VO2 were >50% greater in the cancer group compared to controls (P < 0.05). Women with breast cancer had lower lung diffusing capacity for carbon monoxide (DLCO), respiratory and limb muscle strength, and ventilatory thresholds during exercise compared with controls (all P < 0.05). During exercise, indices of ventilatory efficiency were similar to controls, but inspiratory capacity (IC) was lower and breathing pattern was more rapid and shallow in the cancer group (P < 0.05). The lower peak VO2 in the cancer group was associated with greater dyspnea intensity, and lower DLCO, IC and ventilatory threshold (all P < 0.05). CONCLUSION Breast cancer survivors had greater peripheral and respiratory muscle weakness, greater reduction of IC, impaired lung diffusion, and evidence of deconditioning compared with controls. Exercise intolerance was multifactorial and correlated well with the combination of these factors as well as with exertional dyspnea. Individualized physiological testing in breast cancer survivors can identify important contributors to exercise intolerance which can be targeted for treatment.
Collapse
Affiliation(s)
- Denis E O'Donnell
- Respiratory Investigation Unit, Department of Medicine, Queen's University & Kingston General Hospital, Kingston, Ontario, Canada.
| | - Katherine A Webb
- Respiratory Investigation Unit, Department of Medicine, Queen's University & Kingston General Hospital, Kingston, Ontario, Canada
| | - Daniel Langer
- Respiratory Investigation Unit, Department of Medicine, Queen's University & Kingston General Hospital, Kingston, Ontario, Canada; Faculty of Kinesiology and Rehabilitation Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
| | - Amany F Elbehairy
- Respiratory Investigation Unit, Department of Medicine, Queen's University & Kingston General Hospital, Kingston, Ontario, Canada; Department of Chest Diseases, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - J Alberto Neder
- Respiratory Investigation Unit, Department of Medicine, Queen's University & Kingston General Hospital, Kingston, Ontario, Canada
| | - Deborah J Dudgeon
- Palliative Care Medicine, Department of Medicine, Queen's University & Kingston General Hospital, Kingston, Ontario, Canada
| |
Collapse
|
8
|
Verbanck S, Hanon S, Schuermans D, Van Parijs H, Vinh-Hung V, Miedema G, Verellen D, Storme G, Fontaine C, Lamote J, De Ridder M, Vincken W. Mild Lung Restriction in Breast Cancer Patients After Hypofractionated and Conventional Radiation Therapy: A 3-Year Follow-Up. Int J Radiat Oncol Biol Phys 2016; 95:937-945. [PMID: 27302510 DOI: 10.1016/j.ijrobp.2016.02.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 01/15/2016] [Accepted: 02/01/2016] [Indexed: 12/25/2022]
Abstract
PURPOSE To assess the effect of radiation therapy on lung function over the course of 3 years. METHODS AND MATERIALS Evolution of restrictive and obstructive lung function parameters was investigated in 108 breast cancer participants in a randomized, controlled trial comparing conventional radiation therapy (CR) and hypofractionated tomotherapy (TT) (age at inclusion ranging 32-81 years). Spirometry, plethysmography, and hemoglobin-corrected diffusing capacity were assessed at baseline and after 3 months and 1, 2, and 3 years. Natural aging was accounted for by considering all lung function parameters in terms of percent predicted values using the most recent reference values for women aged up to 80 years. RESULTS In the patients with negligible history of respiratory disease or smoking (n=77), the greatest rate of functional decline was observed during the initial 3 months, this acute decrease being more marked in the CR versus the TT arm. During the remainder of the 3-year follow-up period, values (in terms of percent predicted) were maintained (diffusing capacity) or continued to decline at a slower rate (forced vital capacity). However, the average decline of the restrictive lung function parameters over a 3-year period did not exceed 9% predicted in either the TT or the CR arm. Obstructive lung function parameters remained unaffected throughout. Including also the 31 patients with a history of respiratory disease or more than 10 pack-years showed a very similar restrictive pattern. CONCLUSIONS In women with breast cancer, both conventional radiation therapy and hypofractionated tomotherapy induce small but consistent restrictive lung patterns over the course of a 3-year period, irrespective of baseline respiratory status or smoking history. The fastest rate of lung function decline generally occurred in the first 3 months.
Collapse
Affiliation(s)
- Sylvia Verbanck
- Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium.
| | - Shane Hanon
- Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium
| | - Daniel Schuermans
- Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium
| | - Hilde Van Parijs
- Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium
| | - Vincent Vinh-Hung
- Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium
| | - Geertje Miedema
- Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium
| | - Dirk Verellen
- Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium
| | - Guy Storme
- Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium
| | - Christel Fontaine
- Department of Senology and Oncologic Surgery, University Hospital UZ Brussel, Brussels, Belgium
| | - Jan Lamote
- Department of Senology and Oncologic Surgery, University Hospital UZ Brussel, Brussels, Belgium
| | - Mark De Ridder
- Department of Radiotherapy, University Hospital UZ Brussel, Brussels, Belgium
| | - Walter Vincken
- Respiratory Division, University Hospital UZ Brussel, Brussels, Belgium
| |
Collapse
|
9
|
Van Parijs H, Reynders T, Heuninckx K, Verellen D, Storme G, De Ridder M. Breast conserving treatment for breast cancer: dosimetric comparison of different non-invasive techniques for additional boost delivery. Radiat Oncol 2014; 9:36. [PMID: 24467916 PMCID: PMC3907792 DOI: 10.1186/1748-717x-9-36] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Accepted: 01/09/2014] [Indexed: 11/29/2022] Open
Abstract
Background Today it is unclear which technique for delivery of an additional boost after whole breast radiotherapy for breast conserved patients should be state of the art. We present a dosimetric comparison of different non-invasive treatment techniques for additional boost delivery. Methods For 10 different tumor bed localizations, 7 different non-invasive treatment plans were made. Dosimetric comparison of PTV-coverage and dose to organs at risk was performed. Results The Vero system achieved an excellent PTV-coverage and at the same time could minimize the dose to the organs at risk with an average near-maximum-dose (D2) to the heart of 0.9 Gy and the average volume of ipsilateral lung receiving 5 Gy (V5) of 1.5%. The TomoTherapy modalities delivered an average D2 to the heart of 0.9 Gy for the rotational and of 2.3 Gy for the static modality and an average V5 to the ipsilateral lung of 7.3% and 2.9% respectively. A rotational technique offers an adequate conformity at the cost of more low dose spread and a larger build-up area. In most cases a 2-field technique showed acceptable PTV-coverage, but a bad conformity. Electrons often delivered a worse PTV-coverage than photons, with the planning requirements achieved only in 2 patients and with an average D2 to the heart of 2.8 Gy and an average V5 to the ipsilateral lung of 5.8%. Conclusions We present advices which can be used as guidelines for the selection of the best individualized treatment.
Collapse
Affiliation(s)
- Hilde Van Parijs
- UZ Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
| | | | | | | | | | | |
Collapse
|